GlassScriptPhysician profile
Sara E Zuchowski
NPI 1992817266
$3,161.09
in general payments reported to CMS, 2019-2025
19 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $214 · 2021: $183 · 2022: $579 · 2023: $785 · 2024: $479 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $873.72 | 2019-2025 | Rexulti |
| Abbvie INC. | $780.75 | 2022-2025 | Vraylar |
| Lundbeck LLC | $348.88 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $326.68 | 2022-2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.62 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $127.87 | 2022-2024 | Spravato |
| Allergan, INC. | $68.55 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $67.39 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $67.28 | 2023-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $66.87 | 2022-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $60.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.03 | 2020-2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.30 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $30.19 | 2019-2021 | |
| Almatica Pharma LLC | $16.78 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $16.58 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.40 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $14.79 | 2022 | |
| Validus Pharmaceuticals LLC | $3.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Zuchowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.